KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $358,108 | -17.7% | 11,233 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $435,310 | +9.8% | 10,834 | +16.7% | 0.00% | 0.0% |
| Q1 2023 | $396,555 | -9.3% | 9,287 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $437,078 | +36.2% | 9,102 | +6.6% | 0.00% | +50.0% |
| Q3 2022 | $321,000 | +47.9% | 8,542 | +8.7% | 0.00% | +100.0% |
| Q2 2022 | $217,000 | -48.5% | 7,858 | +1.4% | 0.00% | -50.0% |
| Q1 2022 | $421,000 | -13.2% | 7,748 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $485,000 | +43.5% | 8,293 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $338,000 | -8.9% | 8,541 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $371,000 | -22.1% | 8,744 | +13.1% | 0.00% | -50.0% |
| Q1 2021 | $476,000 | -11.0% | 7,731 | +2.0% | 0.00% | 0.0% |
| Q4 2020 | $535,000 | +232.3% | 7,581 | +82.0% | 0.00% | +100.0% |
| Q3 2020 | $161,000 | +0.6% | 4,165 | -2.3% | 0.00% | 0.0% |
| Q2 2020 | $160,000 | – | 4,261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 321,300 | $12,087,000 | 4.99% |
| First Light Asset Management, LLC | 598,213 | $22,505,000 | 2.28% |
| Nantahala Capital Management | 845,692 | $31,815,000 | 2.06% |
| CHI Advisors LLC | 200,229 | $7,533,000 | 2.03% |
| Fairmount Funds Management LLC | 272,498 | $10,251,000 | 1.80% |
| Altium Capital Management LP | 88,000 | $3,311,000 | 1.21% |
| Orbimed Advisors | 1,679,417 | $63,180,000 | 1.17% |
| SPHERA FUNDS MANAGEMENT LTD. | 206,819 | $7,781,000 | 1.08% |
| Parkman Healthcare Partners LLC | 99,927 | $3,759,000 | 1.07% |
| Soleus Capital Management, L.P. | 146,000 | $5,493,000 | 0.75% |